SCHEMBL5686145

SCHEMBL5686145

COCCN1CCN(CCCOc2ccc(Nc3ncc(C(=O)Nc4c(C)cccc4C)cn3)cc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 2/20 0.50
KDR P35968 7/20 0.48
LCK P06239 4/20 0.48
SRC P12931 3/20 0.48
MAPK14 Q16539 2/20 0.48
BTK Q06187 3/20 0.48
EGFR P00533 5/20 0.46
ITK Q08881 1/20 0.46
JAK3 P52333 1/20 0.46
MET P08581 3/20 0.46
INSR P06213 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496504 0.94 KDR (0.52) TNK2KDRLCKSRCMAPK14
SCHEMBL4496395 0.93 TNK2 (0.56) TNK2KDRLCKSRCMAPK14
SCHEMBL5686260 0.89 KDR (0.49) TNK2KDRLCKSRCMAPK14
SCHEMBL4497531 0.88 KDR (0.47) TNK2KDRLCKSRCMAPK14
SCHEMBL5689079 0.88 KDR (0.47) TNK2KDRLCKSRCMAPK14
SCHEMBL4500256 0.86 KDR (0.50) TNK2KDRLCKSRCMAPK14
SCHEMBL5686300 0.86 KDR (0.50) TNK2KDRLCKSRCMAPK14
SCHEMBL4495452 0.85 EGFR (0.48) KDRLCKSRCMAPK14BTK
SCHEMBL5686279 0.85 CSF1R (0.50) TNK2KDRLCKSRCMAPK14
SCHEMBL4503003 0.84 MET (0.45) KDRLCKSRCMAPK14BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed